Immunomedics Obtains First Milestone Payment From Nycomed
As per the agreement, Immunomedics could potentially receive up to $580m from Nycomed upon achievement of certain clinical, regulatory, and sales-based milestones. The agreement also provides the company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.